أعرض في EDS

Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

التفاصيل البيبلوغرافية
العنوان:	Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
المؤلفون:	Carmelo Carlo-Stella, Stephen Ansell, Pier Luigi Zinzani, John Radford, Kami Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana Advani, Paolo Caimi, René-Olivier Casasnovas, Tatyana Feldman, Brian Hess, Mariana Bastos-Oreiro, Sunil Iyengar, Sandy Eisen, Yanina Negievich, Luqiang Wang, Jens Wuerthner, Alex F. Herrera
المصدر:	Clinical Lymphoma Myeloma and Leukemia. 22:S162
بيانات النشر:	Elsevier BV, 2022.
سنة النشر:	2022
مصطلحات موضوعية:	Cancer Research, Oncology, Hematology
تدمد:	2152-2650
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_________::2781e078a13508bfb25f51d1b2597dc9Test https://doi.org/10.1016/s2152-2650Test(22)00998-3
حقوق:	CLOSED
رقم الانضمام:	edsair.doi...........2781e078a13508bfb25f51d1b2597dc9
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	21522650